Q-omics provides the consensus-scored RPL10AP2 profile across patient tissues and cancer cell-line models. RPL10AP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL10AP2 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RPL10AP2 RNA expression shows 15,326 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, LIHC, and ACC as cancer lineages where RPL10AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10AP2 survival associations across molecular data types. RPL10AP2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10AP2 RNA expression–survival associations across cancer types. High RPL10AP2 expression shows unfavorable associations in STAD, ACC, PAAD and LUAD, but favorable associations in LUSC and MESO. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify STAD as the clearest survival context for RPL10AP2 RNA expression.
This table summarizes RPL10AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10AP2 shows lower tumor expression in BLCA, BRCA and UCEC and higher tumor expression in LIHC, KIRC and COAD. The LIHC box plot shows higher RPL10AP2 RNA expression in tumor versus normal tissue (log2 FC = +0.309, t-test p < 0.001).
This table shows molecular features associated with RPL10AP2 in patient tissues and cancer cell lines. In patient samples, RPL10AP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
